Improved overall survival in melanoma with combined dabrafenib and trametinib.

@article{Robert2015ImprovedOS,
  title={Improved overall survival in melanoma with combined dabrafenib and trametinib.},
  author={C. Robert and B. Karaszewska and J. Schachter and P. Rutkowski and A. Mackiewicz and D. Stroiakovski and M. Lichinitser and R. Dummer and F. Grange and L. Mortier and V. Chiarion-Sileni and K. Drucis and I. Krajsov{\'a} and A. Hauschild and P. Lorigan and P. Wolter and G. Long and K. Flaherty and P. Nathan and A. Ribas and A. Martin and P. Sun and W. Crist and J. Legos and S. Rubin and S. Little and D. Schadendorf},
  journal={The New England journal of medicine},
  year={2015},
  volume={372 1},
  pages={
          30-9
        }
}
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients. METHODS In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a… Expand

Paper Mentions

Interventional Clinical Trial
The co-primary objectives will be to assess the safety and quality of life under treatment.  
ConditionsAdvanced or Metastatic Melanoma, Advanced or Metastatic NSCLC
InterventionDrug
Interventional Clinical Trial
This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.  
ConditionsMelanoma
InterventionDrug
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.
  • G. Long, J. Weber, +23 authors K. Flaherty
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAFV600 Mutation
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
  • G. Long, K. Flaherty, +28 authors J. Grob
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
  • Kevin B Kim, R. Kefford, +17 authors K. Lewis
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Improved survival with ipilimumab in patients with metastatic melanoma.
...
1
2
3
4
...